#
2 days agoDiscover howGLP-1therapycan help manageprediabetes, support weight loss, and improve blood sugar control. Learn more on the Genesis Lifestyle Medicine blog!
Abstract Background SGLT-2 inhibitors (SGLT-2i) andGLP-1receptor agonists (GLP-1RA) are two widely used classes of medications in thetreatmentof diabetes, each demonstrating significant efficacy and adoption. These medications have shown promising results in glycemic control and offer additional health benefits such as weight loss and cardiovascular protection. The objective of our meta ...
Jan 8, 2026Clinical outcomes • Glycemic and weight loss efficacy - GLP-1-based therapies reduce A1C by approximately1to 2 percentage points. They lead to weight loss, which varies with the individual drug. The dual GIP andGLP-1receptor agonist tirzepatide has greater glycemic and weight-reducing efficacy compared with either class of agent alone.
Jun 6, 2024More than 19 years after the introduction of the first glucagon-like peptide1receptor (GLP1R) agonist for thetreatmentof type 2 diabetes and 10 years after the first approval for obesity, two distinct waves of innovation herald new opportunities for broadening the use of new molecules that act primarily through or in combination with medicines that enhanceGLP-1action, hereafter ...
Nov 15, 2025The Perspective onprediabetesas a potential indication forGLP-1therapyraises an important clinical and policy question [1]. Any new indication should rest on outcomes that matter for patients ...
If you have Type 2 diabetes or obesity,GLP-1agonists might be a helpful part of yourtreatmentplan. Learn more.
Jun 14, 2024BackgroundPrediabetesis a condition preceding the development of diabetes and is associated with an increased risk of a number of complications. The primary mode of management is thought to be lifestyle modification. Pharmacologicaltherapy, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), were not well addressed in the literature and were only evaluated in trials as secondary ...
6 days agoIn the medical field, welcome to acronyms.GLP-1stands for glucagon-like peptide-1, and this is a hormone in the body. When we talk aboutGLP-1sorGLP-1agonists as a medication, this means that these are manufactured substances that cause the same action in the body as the naturally occurring hormone would. Kristen Meinzer: And how doGLP-1s...
6 days agoResearchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified forGLP-1treatmenthad a higher risk of type 2 diabetes, suggesting ...
Jun 1, 2024Abstract Background Glucagon-like peptide-1 receptor agonist (GLP-1RA) is incretin-basedtherapythat possessed significant glucose lowering and weight loss properties. The present study aims to analyze the efficacy ofGLP-1RA in the management of overweight/obese individuals withprediabetes.
3 days agoGlenmark Pharmaceuticals Ltd announced the launch of GLIPIQⓇ (semaglutide) in India for thetreatmentof Type 2 Diabetes Mellitus, aiming to makeGLP-1therapysignificantly more affordable and accessible. The introduction addresses a key barrier in diabetes care, where patients often delay advanced injectabletreatmentsdue to high costs and complexity. GLIPIQⓇ has been approved by the ...
3 days agoGlenmark Pharmaceuticals introduces Glipiq, an affordable semaglutide generic for type-2 diabetes, with weekly prices starting at ₹325. Available in vials and pre-filled pens with multiple strengths, the drug aims to enhance accessibility toGLP-1therapy.
7 days agoObesityTreatmentPlus Other Benefits TheGLP-1medications are administered by injection, although an oral form of semaglutide (Rybelsus ®) is available (see "About theGLP-1s"). All of the medications improve blood sugar control, lowering hemoglobin A1c by1% or more, depending on the drug and dosage, Dr. Sunder says.
Patients with pre-existing mental health conditions require closer monitoring when startingGLP-1therapyGLP-1receptor agonists have transformed diabetes and obesitytreatment, but emerging research reveals complex interactions between these medications and mental health that every patient and provider should understand.
GLP-1receptor agonists like semaglutide and liraglutide have transformed diabetes and weight management, but emerging reports link these medications to delayed gastric emptying and potential gastroparesis development. Understanding this connection helps patients and providers make informedtreatmentdecisions.
TodayCommenting on the launch, Mr. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., said, "Affordability is one of the biggest barriers to initiating advanced diabetestherapyin India. With GLIPIQⓇ, we are setting a new benchmark in affordability forGLP-1therapy, with weeklytreatmentstarting at ₹325.
3 days agoGlenmark Pharmaceuticals Ltd (BSE: 532296 | NSE: GLENMARK) entered India's newly opened generic semaglutide market on March 21, 2026, launching GLIPIQ, aGLP-1receptor agonist, for the management of Type 2 Diabetes Mellitus at a weeklytreatmentcost starting at Rs 325. The launch lands on the precise day Novo Nordisk's last remaining Indian patent on semaglutide expired, triggering a ...
2 days agoThe Science BehindGLP-1+ Lifestyle Peer-reviewed evidence on why nutrition, exercise, and behavioral interventions matter alongsideGLP-1receptor agonisttherapy— and what outcomes look like without them.
1 day agoIt also offers a cost-effectivetreatmentpathway, helping expand access totherapyandtreatmentadherence. The expected weekly cost oftreatmentwith GLIPIQⓇ vials range from ₹325 to ₹440, significantly lowering the cost barrier to initiateGLP-1therapyin India and establishing a more affordable entry point into this class oftreatment.
Setting a new benchmark in affordability forGLP-1therapy, with weeklytreatmentstarting at ₹325 Mumbai, India, March 21, 2026: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company, today announced the launch of GLIPIQR (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability forGLP-1therapy...
3 days agoDr Reddy's Laboratories enters theGLP-1therapysegment with Obeda®, aiming to expand access to advanced diabetes care in India Dr. Reddy's Laboratories has launched its semaglutide injection, marketed as Obeda, marking its entry into theGLP-1receptor agonisttherapysegment for the management of type 2 diabetes in India.
4 days agoProduct Specifications and Pricing GLIPIQ® introduces a new benchmark inGLP-1therapyaffordability, addressing one of the primary barriers to advanced diabetestreatmentin India. The product is available in two distinct formulations designed to meet different patient needs andtreatmentstages.
3 days agoGlenmark Pharmaceuticals has announced the launch of GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), positioning it as a more affordableGLP-1therapyaimed at expanding access to advanced diabetestreatment.
7 days agoAreGLP-1agonists psychiatric drugs? The neuroscience of reward, new addiction trial data, and a dosing hypothesis that reframes anhedonia.
3 days agoA CareEdge Ratings analysis places India'sGLP‑1market at the cusp of explosive growth, with domestic demand for diabetes and weight‑management therapies set to multiply fivefold by 2030.
3 days agoThis will be available in both vial and pre-filled pen formulations. The expected weekly cost oftreatmentwith GLIPIQⓇ vials range from ₹325 to ₹440 (Rs 1,300 to Rs 1,760 monthly), significantly lowering the cost barrier to initiateGLP-1therapyin India and establishing a more affordable entry point into this class oftreatment.
Feb 27, 2025TreatmentLiving with type 2 diabetes involves learning about the condition and lifestyle changes. Diabetes education is an important part of managing the condition. Management includes: Healthy eating. Regular exercise. Weight loss if needed. Diabetes medicine or insulintherapyif needed. Keeping track of blood sugar. These steps make it more likely that blood sugar will stay in a healthy ...
Key TakeawaysGLP-1medications like Wegovy are FDA-approved for weight loss in non-diabetic adults with BMI ≥30 or ≥27 with comorbidities Non-diabetics may experience more pronounced side effects since they don't have insulin resistance to bufferGLP-1'seffects Weight loss results in non-diabetics average 10-15% of body weight over 68 weeks with proper dosing Off-label use of diabetes ...
Ozempic® (semaglutide) injection is a once-weeklyGLP-1RA medicine that, along with diet and exercise, may help improve blood sugar in adults with type 2 diabetes. Read Important Safety Information, including Boxed Warning.
WhileGLP-1drugs offer remarkable benefits for diabetes control and weight loss, some patients develop gastroparesis, a serious condition where the stomach muscles fail to contract normally. Understanding this connection helps patients recognize warning signs early and work with healthcare providers to manage theirtreatmentsafely.